Glympse’s $7.5 million venture capital haul topped the list of tech, biotech, and cleantech equity deals in Wahingtion state last month, according to data compiled by our partners at CB Insights. Founded by former Microsofties, Glympse is a “social GPS” offering that allows users to broadcast their whereabouts in real time, kind of like a published tracking service. The Series B round was led by Menlo Ventures and Ignition Partners.
The second-largest equity fundraising went to Adaptive TCR, a Fred Hutchinson Cancer Research Center spinoff that uses software, cloud computing, and DNA sequencers to profile human immune systems. Adaptive TCR says it’s planning to use the new cash infusion to adapt its technology for tests on various forms of cancer or autoimmune diseases. Adaptive TCR declined to say who the money came from, other than it was from individuals and not VCs.
Two companies were tied for third in June with $3.5 million raised: PressPlane and buuteeq.
PressPlane’s Series B round, led by Madrona Venture Group and including RealNetworks founder Rob Glaser, is aimed at Zapd, a service that allows users to design a webpage from their smartphones. PressPlane had previously introduced Inkd, an online graphic design service. PressPlane is headed by Kelly Smith of incubator/investment firm Curious Office.
Buuteeq focuses on digital marketing software for independent hotels. Its Series A financing was led by aQuantive co-founder Mike Galgon and angel investor Geoff Entress, withparticipation from Benaroya Capital and others. Buuteeq also is led by former Microsofties.
Coming in fifth was the $900,000 raised by EquaShip (it used to be called ShipSweet), a startup that wants to disrupt UPS and FedEx by targeting small- and medium-sized business, including online merchants. EquaShip, led by Ron Wiener, aggregates lots of smaller shipments and links them with regional shipping providers to deliver better prices typically enjoyed by the bigger guys. The money came from unnamed angels, and Newell Rubbermaid also joined as a strategic investor.
Check out the chart below for the full rundown of equity deals of $500,000 or more in June in tech, biotech, and cleantech.